Loading clinical trials...
Loading clinical trials...
The AnchorDx UriFind™ Bladder Cancer Assay is designed to detect 2 DNA methylation biomarkers in urine specimens from patients 22 years or older suspected of having bladder cancer. Results from the as...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
AnchorDx Medical Co. Ltd. US
Collaborators
NCT07217171 · Bladder Cancer, Squamous Cell Carcinoma of the Lung, and more
NCT06851663 · Solid Tumor, Solid Carcinoma, and more
NCT05951179 · Non-muscle Invasive Bladder Cancer
NCT07124000 · Adenocarcinoma (NOS), Anal Cancer, and more
NCT06682728 · Urothelial Carcinoma, Muscle-invasive Bladder Cancer
Arkansas Urology
Little Rock, Arkansas
Idaho Urologic Institute
Meridian, Idaho
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions